Management of Cardiometabolic Syndrome in the Primary and Secondary Prevention of Cardiovascular Disease

Journal for Nurse Practitioners

Volumn 4, Issue 9, 2008, Pages 673-680

  Ashen, M Dominique ^a  

^a NONE

Author keywords

Adipose tissue; cardiometabolic syndrome; inflammation; insulin resistance; preventive cardiology

Indexed keywords

EID: 53749088472     PISSN: 15554155     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurpra.2008.07.018     Document Type: Article

References (50)

1. Expert Panel on Detection, and Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. Grundy S.M., Cleeman J.I., Bairey Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, and Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
4. Wilson P.W.F., D'Agostino R.B., Parise H., Sullivan L., and Meigs J.B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112 20 (2005) 3066-3072
5. Hanley A., Festa A., D'Agostino R.B., Wagenknecht L.E., Savage P.J., et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 53 (2004) 1773-1781
6. Ford E.S. Risk for all-cause mortality, cardiovascular disease and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28 (2005) 1769-1778
7. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005) 2735-2752
8. Alexander C.M., Landsman P.B., Teutsch S.M., and Haffner S.M. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
9. Nesto R.W. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 116 suppl 5A (2004) 11s-22s
10. Gami A.S., Witt B.J., Howard D.E., Erwin P.J., Gami L.A., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49 (2007) 403-414
11. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
12. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among US Adults. Diabetes Care 27 (2004) 2444-2449
13. Lemieux I., Pascot A., Couillard C., Lamarche B., Tchernof A., et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small dense LDL-C) in men?. Circulation 102 (2000) 179-184
14. Carr D.B., Utzschneider K.M., Hull R.L., Kodama K., Retzlaff B.M., et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53 (2004) 2087-2094
15. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
16. Ferrannini E., Haffner S.M., Mitchell B.D., and Stern M.P. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34 (1991) 416-422
17. Berneis K.K., and Krauss R.M. Metabolic origins and clinical significance of LDL-C heterogeneity. J Lipid Res 43 (2002) 1363-1379
18. von Eckardstein A., Hersberger M., and Rohrer L. Current understanding of the metabolic and biological actions of HDL-C. Curr Opin Clin Nutr Metab Care 8 (2005) 147-152
19. Jellinger P.S. Metabolic consequences of hyperglycemia and insulin resistance. Clin Cornerstone 8 (2007) S30-S42
20. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289 (2003) 2560-2572
21. Aronson D., and Rayfield E.J. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 1 (2002) 1-10
22. Juhan-Vague I., Morange P.E., and Alessi M.C. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb 32 (2002) 269-273
23. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1420
24. Wellen K.E., and Hotamisligil G.S. Obesity induced inflammatory changes in adipose tissue. J Clin Investig 112 (2003) 1785-1788
25. Ross R. Atherosclerosis - an inflammatory disease. NEJM 340 (1999) 115-126
26. Pollex R.L., and Hegele R.A. Genetic determinants of the metabolic syndrome. Nat Clin Pract 3 (2006) 482-489
27. WHO. Report of a WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Available at: http://www.staff.newcastle.ac.uk/phillip.home/who_dmc.htm Last accessed June 15, 2008.
28. George K., Alberti M.M., Zimmet P., and Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 366 (2005) 1059-1062
29. Hunt K.J., Resendez R.G., Williams K., Haffner S.M., and Stern M.P. National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study. Circulation 110 (2004) 1251-1257
30. Lorenzo L., Williams K., Hunt K.J., and Haffner S.M. The National Cholesterol Education Program Adult Treatment Panel III, International Diabetes Foundation and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30 1 (2007) 8-13
31. Davis S. Evolving treatments for cardiometabolic syndrome. Manag Care Med 9 (2006) 17-21
32. Michos E.D., Nasir K., Braunstein J.B., Rumberger J.A., Budoff M.J., et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis 184 (2006) 201-206
33. Santos R.D., Nasir K., Tufail K., Meneghelo R.S., Carvalho J., et al. Metabolic syndrome is associated with coronary artery calcium in asymptomatic white Brazilian men considered low-risk by Framingham risk score. Prev Cardiol 10 3 (2007) 141-146
34. Shaw L.J., Raggi P., Schisterman E., Berman D.S., and Callister T.Q. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology 228 3 (2003) 826-833
35. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Kupka M.K., et al. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation 106 (2002) 1189-1191
36. Nassis G.P., Papantakou K., Skenderi K., Triandafillopoulou M., Kavouras S.A., et al. Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin and inflammatory markers in overweight and obese girls. Metabolism 54 (2005) 1472-1479
37. LaMonte M.J., Barlow C.E., Jurca R., Kampert J.B., Church T.S., et al. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation 112 4 (2005) 505-512
38. Lopez-Garcia E., Schulze M.B., Fung T.T., Meigs J.B., Rifai N., et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 80 4 (2004) 1029-1035
39. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., et al. Effect of Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292 (2004) 1440-1446
40. Ebbeling C.B., Leidig M.M., Feldman H.A., Lovesky M.M., and Ludwig D.S. Effects of a low-glycemic load vs low fat diet in obese young adults: a randomized trial. JAMA 297 19 (2007) 2012-2092
41. Available at: www.nhlbi.nih.gov/health/public/heart/obesity/lose_wt/behavior.htm Last accessed June 15, 2008.
42. American Diabetes Association. Clinical practice recommendations. Diabetes Care 28 Suppl 1 (2005) s1-s9
43. Smith Jr. S.C., Blair S.N., Bonow R.O., Brass L.M., Cerqueira M.D., et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic vascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 104 (2001) 1577-1579
44. Pearson T.A., Blair S.N., Daniels S.R., Eckel R.H., Fair J.M., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002) 388-391
45. National Institutes of Health. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults - the evidence report. Obes Res 6 Suppl 2 (1998) 51S-209S
46. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
47. Mosca L., Banka C.L., Benjamin E.J., Berra K., Bushnell C., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 (2007) 1481-1501
48. Yusuf S., Gerstein H., Hoogwerf B., Pogue J., Bosch J., et al. Ramapril and the development of diabetes. JAMA 286 (2001) 1882-1885
49. Lindholm L.H., Ibsen H., Borch-Johnsen K., Olsen M.H., Wachtell K., et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study. J Hypertens 20 9 (2002) 1879-1886
50. Kjeldsen S., Julius S., Mancia G., McInnes G., Hua T., et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high risk hypertensive patients: the VALUE trial. J Hypertens 24 7 (2006) 1045-1412